Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
June 24, 2024 08:00 ET
|
Enlivex Therapeutics Ltd
First patient dosed with AllocetraTM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of peopleThumb osteoarthritis currently has no FDA-approved...
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
June 20, 2024 08:00 ET
|
Enlivex Therapeutics Ltd
Ness-Ziona, Israel, June 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, is...
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
June 17, 2024 08:00 ET
|
Enlivex Therapeutics Ltd
Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of AllocetraTM into the knee as a “last...
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
June 03, 2024 08:00 ET
|
Enlivex Therapeutics Ltd
● First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy ●Third study of AllocetraTM in...
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
May 29, 2024 16:15 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
May 28, 2024 08:12 ET
|
Enlivex Therapeutics Ltd
Single healthcare-focused institutional investor $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full of clinical milestone-linked warrants ...
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
April 29, 2024 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today...
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
April 22, 2024 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
April 16, 2024 07:50 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
April 11, 2024 14:58 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...